FI79840C - Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart, kristallint glukonatsalt av m-amsa. - Google Patents
Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart, kristallint glukonatsalt av m-amsa. Download PDFInfo
- Publication number
- FI79840C FI79840C FI810180A FI810180A FI79840C FI 79840 C FI79840 C FI 79840C FI 810180 A FI810180 A FI 810180A FI 810180 A FI810180 A FI 810180A FI 79840 C FI79840 C FI 79840C
- Authority
- FI
- Finland
- Prior art keywords
- amsa
- solution
- salt
- process according
- water
- Prior art date
Links
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 title claims description 36
- 230000001225 therapeutic effect Effects 0.000 title description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 14
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 14
- 239000000174 gluconic acid Substances 0.000 claims description 14
- 235000012208 gluconic acid Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 150000002596 lactones Chemical class 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- -1 9-acridinylamino Chemical group 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000006207 intravenous dosage form Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11480980A | 1980-01-24 | 1980-01-24 | |
| US11480980 | 1980-01-24 | ||
| US19435080 | 1980-10-17 | ||
| US06/194,350 US4322424A (en) | 1980-01-24 | 1980-10-17 | Crystalline glucoconate salt of m-AMSA and compositions containing same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI810180L FI810180L (fi) | 1981-07-25 |
| FI79840B FI79840B (fi) | 1989-11-30 |
| FI79840C true FI79840C (fi) | 1990-03-12 |
Family
ID=26812557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI810180A FI79840C (fi) | 1980-01-24 | 1981-01-22 | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart, kristallint glukonatsalt av m-amsa. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4322424A (en, 2012) |
| AT (1) | AT380474B (en, 2012) |
| AU (1) | AU543758B2 (en, 2012) |
| CA (1) | CA1252103A (en, 2012) |
| CH (1) | CH648023A5 (en, 2012) |
| DE (1) | DE3102026A1 (en, 2012) |
| DK (1) | DK29781A (en, 2012) |
| FI (1) | FI79840C (en, 2012) |
| FR (1) | FR2474493B1 (en, 2012) |
| GB (1) | GB2068729B (en, 2012) |
| GR (1) | GR82326B (en, 2012) |
| IE (1) | IE50884B1 (en, 2012) |
| IT (1) | IT1170638B (en, 2012) |
| LU (1) | LU83081A1 (en, 2012) |
| NL (1) | NL8100292A (en, 2012) |
| SE (1) | SE453497B (en, 2012) |
| YU (1) | YU42552B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU186383B (en) * | 1981-02-27 | 1985-07-29 | Biogal Gyogyszergyar | Process for producing new citostatic amni-acridie-alpha, beta-bracket-d-bracket closed, or aracket-l-bracket closed-n-glycoside derivatives and salts |
| US4575509A (en) * | 1983-01-31 | 1986-03-11 | Bristol-Myers Company | Water-soluble formulations of m-AMSA with pyroglutamic acid |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1674923A (en) * | 1924-04-12 | 1928-06-26 | Schnorf Carl | Process for the production of carbohydrate-acridine compounds and solutions thereof |
| US3839344A (en) * | 1973-03-28 | 1974-10-01 | Schering Corp | N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid |
| US4258191A (en) * | 1979-03-29 | 1981-03-24 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Multi-step process for the production of methanesulfon-m-anisidide, 4'-(9-acridinylamino)- |
| DE3063905D1 (en) * | 1979-09-14 | 1983-07-28 | New Zealand Dev Finance | Compounds having antitumour properties, process for their preparation, these compounds for use as antitumour agents and pharmaceutical compositions containing them |
| ZA811304B (en) * | 1980-03-11 | 1982-06-30 | Warner Lambert Co | Pharmaceutical salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide |
-
1980
- 1980-10-17 US US06/194,350 patent/US4322424A/en not_active Expired - Lifetime
-
1981
- 1981-01-20 YU YU145/81A patent/YU42552B/xx unknown
- 1981-01-21 NL NL8100292A patent/NL8100292A/nl not_active Application Discontinuation
- 1981-01-21 SE SE8100341A patent/SE453497B/sv not_active IP Right Cessation
- 1981-01-21 IT IT47604/81A patent/IT1170638B/it active
- 1981-01-21 AU AU66512/81A patent/AU543758B2/en not_active Ceased
- 1981-01-22 DK DK29781A patent/DK29781A/da not_active Application Discontinuation
- 1981-01-22 DE DE19813102026 patent/DE3102026A1/de active Granted
- 1981-01-22 FI FI810180A patent/FI79840C/fi not_active IP Right Cessation
- 1981-01-22 CA CA000369109A patent/CA1252103A/en not_active Expired
- 1981-01-23 LU LU83081A patent/LU83081A1/fr unknown
- 1981-01-23 FR FR8101233A patent/FR2474493B1/fr not_active Expired
- 1981-01-23 IE IE119/81A patent/IE50884B1/en unknown
- 1981-01-23 GB GB8102175A patent/GB2068729B/en not_active Expired
- 1981-01-23 GR GR63955A patent/GR82326B/el unknown
- 1981-01-26 CH CH484/81A patent/CH648023A5/de not_active IP Right Cessation
- 1981-01-26 AT AT0032681A patent/AT380474B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA1252103A (en) | 1989-04-04 |
| YU42552B (en) | 1988-10-31 |
| AT380474B (de) | 1986-05-26 |
| AU6651281A (en) | 1981-07-30 |
| FI79840B (fi) | 1989-11-30 |
| US4322424A (en) | 1982-03-30 |
| FR2474493B1 (fr) | 1985-12-13 |
| FI810180L (fi) | 1981-07-25 |
| NL8100292A (nl) | 1981-08-17 |
| GR82326B (en, 2012) | 1984-12-13 |
| ATA32681A (de) | 1985-10-15 |
| YU14581A (en) | 1983-06-30 |
| AU543758B2 (en) | 1985-05-02 |
| IT1170638B (it) | 1987-06-03 |
| DK29781A (da) | 1981-07-25 |
| GB2068729B (en) | 1983-10-19 |
| SE8100341L (sv) | 1981-07-25 |
| DE3102026A1 (de) | 1982-03-04 |
| IT8147604A0 (it) | 1981-01-21 |
| LU83081A1 (fr) | 1981-09-10 |
| IT8147604A1 (it) | 1982-07-21 |
| DE3102026C2 (en, 2012) | 1990-05-31 |
| FR2474493A1 (fr) | 1981-07-31 |
| GB2068729A (en) | 1981-08-19 |
| IE50884B1 (en) | 1986-08-06 |
| IE810119L (en) | 1981-07-24 |
| SE453497B (sv) | 1988-02-08 |
| CH648023A5 (de) | 1985-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2750768B1 (en) | Decitabine derivative formulations | |
| EA001903B1 (ru) | Интраназальные композиции для лечения сексуальных расстройств | |
| KR101319516B1 (ko) | 퓨린 유도체 | |
| KR20110026311A (ko) | 엔테카비어의 신규한 염 | |
| CA1160571A (en) | Antitumor compositions | |
| FI79840B (fi) | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart, kristallint glukonatsalt av m-amsa. | |
| FI71319B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbart vicaminsackarinat | |
| JP4566128B2 (ja) | イリノテカン塩酸塩の結晶多形の製造方法 | |
| JP7148642B2 (ja) | 安定したアザシチジン含有医薬組成物の製造方法 | |
| CN116621856A (zh) | 一种新颖的氨基甲酸酯类化合物及其用途 | |
| US5034397A (en) | Stable, water soluble salt compositions of M-AMSA in 1-methyl-2-pyrrolidinone | |
| WO2013032184A2 (ko) | 피라지노-트리아진 유도체를 포함하는 조성물 | |
| FI80023C (fi) | Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara kristallina laktatacetonatsolvat av m-amsa. | |
| EP1764102A1 (en) | Quinolone-containing medicinal composition | |
| JPH0343251B2 (en, 2012) | ||
| CA1253160A (en) | Pharmaceutical salts of 4'-(9-acridinylamino) methanesulfon-manisidide | |
| US4419358A (en) | Isethionic acid salt of 9-cyclohexyl-2-propoxy-9H-purine-6-amine and compositions containing an effective bronchodilating concentration of it | |
| JP4829120B2 (ja) | イリノテカン酸付加塩 | |
| US20220396593A1 (en) | Synthesis and characterization of vanadium complexes | |
| CN105367622B (zh) | 一种阿加曲班化合物 | |
| JPH032862B2 (en, 2012) | ||
| US4575509A (en) | Water-soluble formulations of m-AMSA with pyroglutamic acid | |
| US4626541A (en) | Water soluble salt composition of m-AMSA | |
| CA1159368A (en) | Antitumor compositions | |
| JPH0315632B2 (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: BRISTOL-MYERS SQUIBB COMPANY |